Nexentis Technologies Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nexentis Technologies Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $263.4K | Apr 1, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $210.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $263.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $394.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $438.1K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $232.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $175.8K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $426.6K | Mar 30, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $45.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $208.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $235.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $302.2K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $188.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $31.3K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $315.5K | Mar 30, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.00M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($5.19M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($6.52M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.74M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.82M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($1.59M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.97M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($356.9K) | Mar 30, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.23M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.28M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.82M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.70M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($1.35M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.93M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($518.7K) | Mar 30, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $179.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $369.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.94M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $770.8K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $538.7K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $417.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $615.6K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $357.1K | Mar 30, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.81M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.42M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.23M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.10M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.11M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($798.7K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.24M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($506.5K) | Mar 30, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.0K | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $51.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $67.7K | Mar 27, 2023 |
| FY2020 | Dec 31, 2019 | $23.3K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.5K | Mar 30, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.41M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.47M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.24M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.49M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.60M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $687.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $664.7K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $859.2K | Mar 30, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.68M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $892.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $786.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $754.9K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.18M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.15M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.07M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $647.7K | Mar 30, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.01M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.75M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.48M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.85M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.48M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($436.2K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($381.1K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $218.2K | Mar 30, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.29M | Mar 31, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.56M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($34.55M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($29.36M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($22.84M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($17.10M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($12.28M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($10.68M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($8.71M) | Mar 30, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.83M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.92M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.70M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.75M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $242.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $290.8K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $439.8K | Mar 30, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $8.4K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $16.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $22.2K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $60.8K | Mar 30, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (27) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 10 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 27, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (27) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 10 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.77M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 344,741 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 2.96M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 688,272 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 2.81M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 1.61M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 1.46M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 9.23M | Mar 30, 2020 |